(19)
(11) EP 3 915 565 A3

(12) EUROPEAN PATENT APPLICATION

(88) Date of publication A3:
16.03.2022 Bulletin 2022/11

(43) Date of publication A2:
01.12.2021 Bulletin 2021/48

(21) Application number: 21174259.8

(22) Date of filing: 17.03.2014
(51) International Patent Classification (IPC): 
A61K 31/519(2006.01)
A61K 47/18(2017.01)
A61K 9/14(2006.01)
A61P 3/00(2006.01)
A61K 31/197(2006.01)
A61K 31/4188(2006.01)
A61K 31/455(2006.01)
A61K 31/525(2006.01)
A61K 31/714(2006.01)
A61K 33/00(2006.01)
 A61K 47/22(2006.01)
A61K 9/08(2006.01)
A61P 19/06(2006.01)
A61K 9/00(2006.01)
A61K 31/198(2006.01)
A61K 31/4415(2006.01)
A61K 31/51(2006.01)
A61K 31/593(2006.01)
A61K 31/375(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 9/0095; A61K 31/197; A61K 31/198; A61K 31/375; A61K 31/4188; A61K 31/4415; A61K 31/455; A61K 31/51; A61K 31/519; A61K 31/525; A61K 31/593; A61K 31/714; A61K 47/183; A61P 19/06; A61P 3/00; A61K 33/00
 
C-Sets:
  1. A61K 31/525, A61K 2300/00;
  2. A61K 31/51, A61K 2300/00;
  3. A61K 31/714, A61K 2300/00;
  4. A61K 31/197, A61K 2300/00;
  5. A61K 31/4188, A61K 2300/00;
  6. A61K 33/00, A61K 2300/00;
  7. A61K 31/198, A61K 2300/00;
  8. A61K 31/593, A61K 2300/00;
  9. A61K 31/519, A61K 2300/00;
  10. A61K 31/375, A61K 2300/00;
  11. A61K 31/455, A61K 2300/00;
  12. A61K 31/4415, A61K 2300/00;
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 15.03.2013 US 201361790414 P

(62) Application number of the earlier application in accordance with Art. 76 EPC:
14764884.4 / 3001814

(71) Applicant: XORTX Therapeutics Inc.
Calgary, Alberta T2P 4K9 (CA)

(72) Inventors:
  • Davidoff, Allen
    Calgary, T3H 5Z7 (CA)
  • Bolvin, Taryn
    Surrey, BC V4A 9W5 (CA)

(74) Representative: Di Giovine, Paolo et al
Società Italiana Brevetti S.p.A. Piazza di Pietra, 38-39
00186 Roma
00186 Roma (IT)

   


(54) XANTHINE OXIDASE INHIBITOR FORMULATIONS


(57) Disclosed herein are methods and compositions for involving a xanthine oxidase inhibitor that has enhanced solubility. The compositions described herein include a xanthine oxidase inhibitor combined with an organic base. The compositions can be used to treat a disease or medical condition that involves elevated uric acid levels.







Search report


















Search report